T1	Participants 33 66	South African patients with DLBCL
T2	Participants 89 285	93 de novo diffuse large B-cell lymphoma patients seen between 1995 and 2009 randomly receiving either standard combination chemotherapy (CHOP, n=48) or the identical program with rituximab (n=45)
T3	Participants 2944 2974	South African public hospitals
